Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Faron Pharmaceuticals (FARN) Share Price

Price 200.00p on 05-05-2025 at 05:00:03
Change 0.00p 0%
Buy 0.00p
Sell 0.00p
Buy / Sell FARN Shares
Last Trade: Sell 300.00 at 198.761p
Day's Volume: 0
Last Close: 200.00p
Open: 0.00p
ISIN: FI4000153309
Day's Range 0.00p - 0.00p
52wk Range: 89.00p - 270.00p
Market Capitalisation: £223m
VWAP: 0.00p
Shares in Issue: 112m

Faron Pharmaceuticals (FARN) Latest Trades

Buy/Sell Volume Trade Prc Trade Type Trade Time
Sell* 300 198.761p Ordinary
16:22:58 - 02-May-25
Sell* 4,540 198.761p Ordinary
15:23:07 - 02-May-25
Sell* 157 198.70p Ordinary
13:47:42 - 02-May-25
Buy* 1,000 202.90p Ordinary
11:30:35 - 02-May-25
Sell* 1,000 198.351p Ordinary
10:16:17 - 02-May-25
Sell* 488 186.00p Uncrossing Trade
09:00:28 - 02-May-25
Buy* 5,000 200.00p Ordinary
08:38:14 - 02-May-25
Buy* 50 199.90p Ordinary
08:28:40 - 02-May-25
Buy* 2,500 197.00p Ordinary
08:04:17 - 02-May-25
Buy* 250 195.00p Ordinary
08:02:54 - 02-May-25
See more Faron Pharmaceuticals trades

Faron Pharmaceuticals (FARN) Share Price History

Time period:
to
Date Open High Low Close Volume
2nd May 2025 (Fri) 192.50 200.00 186.00 200.00 15,785
1st May 2025 (Thu) 197.50 197.50 191.00 192.50 8,110
30th Apr 2025 (Wed) 205.00 205.00 197.50 197.50 17,672
29th Apr 2025 (Tue) 205.00 205.00 205.00 205.00 20,913
28th Apr 2025 (Mon) 202.00 196.00 196.00 196.00 6,826
25th Apr 2025 (Fri) 202.50 202.50 200.00 202.00 9,855
24th Apr 2025 (Thu) 210.00 210.00 202.50 202.50 7,150
23rd Apr 2025 (Wed) 210.00 210.00 210.00 210.00 9,741
22nd Apr 2025 (Tue) 210.00 210.00 202.50 210.00 44,291
21st Apr 2025 (Mon) 210.00 210.00 210.00 210.00 0
18th Apr 2025 (Fri) 210.00 210.00 210.00 210.00 0
17th Apr 2025 (Thu) 200.00 210.00 202.50 210.00 70,403
16th Apr 2025 (Wed) 232.50 205.00 196.00 196.00 2,246,417
15th Apr 2025 (Tue) 250.00 259.00 232.50 232.50 159,568
14th Apr 2025 (Mon) 235.00 250.00 240.00 250.00 42,337
11th Apr 2025 (Fri) 226.50 235.00 235.00 235.00 9,561
10th Apr 2025 (Thu) 225.00 230.00 222.50 226.50 29,012
9th Apr 2025 (Wed) 226.50 228.00 220.00 222.00 46,366
8th Apr 2025 (Tue) 217.50 231.50 215.00 223.00 49,357
7th Apr 2025 (Mon) 205.00 215.00 215.00 215.00 56,125
See more Faron Pharmaceuticals price history

Faron Pharmaceuticals (FARN) Regulatory News

Date Source Headline
3rd Mar 2025 12:05 pm RNS FDA Grants Orphan Drug Designation
28th Feb 2025 12:00 pm RNS Notice of Annual General Meeting
27th Feb 2025 7:30 am RNS Positive EMA Opinion on Orphan Drug Designation
27th Feb 2025 7:15 am RNS Annual Report 2024 published
27th Feb 2025 7:00 am RNS Financial Statement 1 January to 31 December 2024
19th Feb 2025 10:00 am RNS Notice of Financial Statement and Annual Report
14th Feb 2025 12:00 pm RNS Holding(s) in Company
11th Feb 2025 7:30 am RNS Change of Broker
6th Feb 2025 3:00 pm RNS Holding(s) in Company
6th Feb 2025 7:00 am RNS Results of Oversubscribed Placing
See more Faron Pharmaceuticals regulatory news

Faron Pharmaceuticals (FARN) Share News

UK shareholder meetings calendar - next 7 days

14th Mar 2025 14:09

Read More

UK earnings, trading statements calendar - next 7 days

20th Feb 2025 14:16

Read More

Faron Pharmaceuticals raises EUR12 million from oversubscribed placing

6th Feb 2025 11:41

(Alliance News) - Faron Pharmaceuticals Ltd on Thursday said it has raised EUR12 million from an oversubscribed placing ahead of upcoming trial results. Read More

IN BRIEF: Faron Pharmaceuticals shares up as presents data on Bexmab

10th Dec 2024 14:31

Faron Pharmaceuticals PLC on Tuesday - Turku, Finland-based developer of cancer immunotherapies - Presents full analysis of positive phase 2 interim data from Bexmab trial at the annual meeting of the Society of Hematology in San Diego. Faron highlights an overall response rate of 80% in refractory or relapsed HMA failed MDS patient population. HMA stands for hypomethylating agents, while MDS stands for myelodysplastic syndromes. Chief Executive Officer Juho Jalkanen says: "With this compelling evidence, we are well positioned to advance to the full phase 2 efficacy readout and actively pursue further regulatory interactions to navigate and refine the pivotal pathway for BLA filing." Read More

Faron announces promising findings from blood cancer drug trial

27th Nov 2024 11:29

(Alliance News) - Faron Pharmaceuticals Ltd on Wednesday reported positive data from an ongoing trial on patients receiving a new treatment for a rare blood cancer. Read More

See more Faron Pharmaceuticals news
FTSE 100 Latest
Value8,596.35
Change99.55

Login to your account

Forgot Password?

Not Registered